Arch Biopartners Inc., of Toronto, said the EMA's Committee for Orphan Medicinal Products issued a positive opinion recommending AB569 for designation as an orphan medicinal product for the treatment of patients with cystic fibrosis. The orphan medicinal products designation is recommended for the two active ingredients of AB569, sodium nitrite and ethylenediaminetetraacetic acid.